NEW YORK--(BUSINESS WIRE)--Trilantic North America, a growth-focused middle market private equity firm, announced today that it has made a substantial growth investment in SOFIE Biosciences ('SOFIE' or the 'Company'), a founder-led radiopharmacy and contract development and manufacturing organization.

纽约--（商业新闻短讯）--Trilantic North America是一家专注于增长的中等市场私人股本公司，今天宣布，它已经对SOFIE Biosciences（“SOFIE”或“公司”）进行了实质性的增长投资，SOFIE Biosciences是一家创始人领导的放射制药和合同开发与制造组织。

The investment was made in partnership with SOFIE's founding team, who will retain a meaningful equity stake and continue to lead the business..

这项投资是与索菲的创始团队合作进行的，他们将保留有意义的股权，并继续领导企业。。

Headquartered in Dulles, Virginia and with 15 locations across the United States, SOFIE is a leading player in the radiopharmaceutical sector, manufacturing more than 567,000 doses annually on behalf of its partners and customers. The growth investment from Trilantic North America will capitalize the business to execute on several growth initiatives, including expanding capacity and points of presence to improve patient access to its growing portfolio of radiopharmaceutical products..

SOFIE总部位于弗吉尼亚州杜勒斯，在美国拥有15个办事处，是放射性制药行业的领先者，每年代表其合作伙伴和客户生产超过567000剂。Trilantic North America的增长投资将利用该业务执行多项增长计划，包括扩大产能和存在点，以改善患者对其不断增长的放射性药物产品组合的访问。。

'We are excited to partner with the SOFIE team to support their vision for continued growth and delivering critical products on a just-in-time basis to patients in need,' said Ted Rosenwasser, Partner at Trilantic North America. 'Molecular imaging is at an exciting inflection point, and we look forward to supporting Patrick, Philipp and the team to expand SOFIE's capability set and drive the Company's impact in this dynamic market.'.

Trilantic North America合伙人特德·罗森瓦瑟（TedRosenwasser）说：“我们很高兴能与索菲团队合作，支持他们持续增长的愿景，并及时向有需要的患者提供关键产品。”分子成像正处于一个令人兴奋的转折点，我们期待着支持Patrick，Philipp和团队扩大SOFIE的能力集，并推动公司在这个充满活力的市场中产生影响。”。

Munesh Advani, Principal at Trilantic North America, added, 'Our investment in SOFIE is another example of Trilantic North America's focus on partnering with founders, families and entrepreneurial management teams to raise their businesses to the next level.'

Trilantic North America负责人穆内什·阿德瓦尼（Munesh Advani）补充说，“我们对索菲的投资是Trilantic North America专注于与创始人、家族和创业管理团队合作的另一个例子，将他们的业务提升到一个新的水平。”

Patrick Phelps, SOFIE Co-Founder, President and CEO, said, “The recent staggering increase in the adoption of radiopharmaceuticals in medicine provides SOFIE, and our scientific community, numerous opportunities to provide value through companion diagnostic development, and manufacturing of diagnostic and therapeutic products, at scale.

SOFIE联合创始人、总裁兼首席执行官帕特里克·菲尔普斯（PatrickPhelps）表示：“最近，放射性药物在医学中的应用惊人地增加，这为SOFIE和我们的科学界提供了许多机会，可以通过伴随的诊断开发以及大规模制造诊断和治疗产品来提供价值。

Such an opportunity comes once in a lifetime. Trilantic is the right partner to make our full vision come true.”.

这样的机会一生只有一次。Trilantic是实现我们全面愿景的最佳合作伙伴。”。

William Blair & Company, LLC acted as financial advisor and Kirkland & Ellis LLP provided legal advice to Trilantic North America. Solomon Partners Securities, LLC acted as financial advisor and Paul, Weiss, Rifkind, Wharton & Garrison LLP provided legal services to SOFIE.

William Blair&Company，LLC担任财务顾问，Kirkland&Ellis LLP为Trilantic North America提供法律咨询。Solomon Partners Securities，LLC担任财务顾问，Paul、Weiss、Rifkind、Wharton&Garrison LLP为SOFIE提供法律服务。

About Trilantic North America

关于Trilantic北美

Trilantic Capital Management L.P. ('Trilantic North America') is a growth-focused middle market private equity firm focused on control and significant minority investments in North America. Trilantic North America's primary investment focus is in the business services and consumer sectors. Trilantic North America has managed or is currently managing seven private equity fund families with aggregate capital commitments of $10.9 billion.

Trilantic Capital Management L.P.（“Trilantic North America”）是一家专注于增长的中等市场私人股本公司，专注于北美的控制权和重大少数股权投资。Trilantic North America的主要投资重点是商业服务和消费部门。Trilantic North America已管理或目前正在管理七个私募股权基金家族，总资本承诺额为109亿美元。

For more information, visit www.trilanticnorthamerica.com..

有关更多信息，请访问www.trilanticnorthamerica.com。。

About SOFIE

关于SOFIE

SOFIE’s vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to deliver on the promise of radiopharmaceuticals.

SOFIE的愿景是通过开发和提供分子诊断和治疗（Theranostics）来改善患者的预后。凭借其强大的放射性药物生产和分销网络，成熟的合同制造服务，以及现在的高价值治疗诊断知识产权，SOFIE准备兑现放射性药物的承诺。

For more information, please visit https://sofie.com or contact info@sofie.com..

有关更多信息，请访问https://sofie.com或联系人info@sofie.com..